Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells

Area of Science:

• Cardiology
• Oncology
• Stem Cell Biology

Background:

• Novel antineoplastic therapies improve cancer survival but can lead to cardiotoxicity, limiting treatment efficacy.
• Cardiotoxicity from cancer treatments necessitates the development of novel cardioprotective strategies.
• There is a critical need for effective experimental models to study chemotherapy-induced cardiomyopathy.

Purpose of the Study:

• To review the utility of human stem cell-derived cardiomyocytes as in vitro models for chemotherapy-induced cardiomyopathy.
• To explore the potential of these models in identifying new therapeutic targets and predicting cardiotoxicity.

Main Methods:

• Review of current literature on stem cell-derived cardiomyocytes in cardiovascular research.
• Discussion of induced pluripotent stem (iPS) cell- and human embryonic stem cell (hESC)-derived cardiomyocytes.
• Analysis of their application in modeling chemotherapy-induced cardiotoxicity.

Main Results:

• Human stem cell-derived cardiomyocytes provide a viable in vitro platform for studying cardiotoxicity mechanisms.
• These models can be used to evaluate the efficacy of potential cardioprotective agents.
• They offer a predictive tool for assessing chemotherapy-induced cardiotoxicity.

Conclusions:

• Human iPS- and hESC-derived cardiomyocytes are valuable tools for understanding and mitigating chemotherapy-induced cardiotoxicity.
• These models facilitate the discovery of novel pharmacological targets for cardioprotection.
• Their use can improve clinical outcomes for cancer patients undergoing cardiotoxic therapies.